How to Access Weight Loss Drugs If You Can't Afford Them

TL;DR: There are six main pathways to access weight loss drugs if you can't afford them: manufacturer patient assistance programs (free medication for qualifying uninsured patients), savings cards ($25 per month copays for commercially insured patients), insurance appeal strategies (over 65% of prior authorization appeals succeed), direct-to-consumer platforms like LillyDirect ($299 to $449 per month for Zepbound), clinical trials (free access to investigational and existing medications), and state Medicaid (only 13 states cover GLP-1s for obesity as of 2026). If none of these pathways work for you, behavioral approaches that target the same underlying drivers of overeating offer a fundamentally different cost structure.

GLP-1 medications work. The evidence is clear, and the results speak for themselves. The problem is that they cost roughly $970 to $1,350 per month without insurance, and even with insurance, the out-of-pocket burden can be hundreds of dollars monthly.

If you've been told a GLP-1 could help you but the price tag stopped you, you're in a large and growing group. Millions of people who could benefit from these medications can't access them. This guide covers every available pathway, from free programs to creative strategies, so you can make an informed decision about which options apply to your situation.

Manufacturer Patient Assistance Programs

Both major GLP-1 manufacturers offer programs for patients who genuinely cannot afford their medications. These are the most generous options available, but eligibility is narrow.

Novo Nordisk (Ozempic and Wegovy)

Novo Nordisk's Patient Assistance Program (PAP) through NovoCare provides free Ozempic to qualifying patients. The eligibility requirements as of 2026:

• U.S. citizen or legal resident
• Household income at or below 200% of the Federal Poverty Level (approximately $31,200 for an individual, $64,400 for a family of four in 2026)
• Uninsured with no prescription drug coverage
• Valid prescription from a licensed healthcare provider
• Medicaid denial letter (if applicable)

The critical limitation: Ozempic is covered by the PAP only for type 2 diabetes, not for weight loss. Wegovy is not covered by the PAP at all, regardless of income or insurance status. This means the manufacturer's own free-medication program excludes the people most commonly seeking GLP-1s for weight management.

Eli Lilly (Mounjaro and Zepbound)

Eli Lilly offers the Lilly Cares Patient Assistance Program with similar income-based eligibility. Mounjaro is available through PAP for qualifying patients with type 2 diabetes. Zepbound availability through PAP is more limited.

What to do: If you meet the income requirements, ask your prescribing provider to help you apply. The application process takes 2 to 4 weeks, and approval lasts for a defined period (typically 12 months, renewable).

Savings Cards and Copay Assistance

If you have commercial insurance but your copay is still too high, manufacturer savings cards can dramatically reduce your out-of-pocket cost.

Novo Nordisk Savings Card:

• Ozempic: as low as $25 per month (up to $150 in savings per fill)
• Wegovy: as low as $25 per month (up to $225 in savings per fill)

Eli Lilly Savings Card:

• Mounjaro: as low as $25 per month
• Zepbound: similar copay reduction program

Who qualifies: Patients with commercial (employer-provided or marketplace) insurance. These savings cards cannot be used with Medicare, Medicaid, TRICARE, or any federal healthcare program.

Who doesn't qualify: Uninsured patients, Medicare beneficiaries, and Medicaid recipients. This exclusion affects a significant portion of the population that needs cost relief most.

Insurance Appeal Strategies

If your insurance denied coverage for a weight loss medication, an appeal is worth pursuing. The success rates are higher than most people realize.

Over 65% of prior authorization appeals for weight loss medications are overturned. In Medicare Advantage plans, the reversal rate exceeds 80% for denials that are actually appealed. The problem is that most denials are never appealed at all.

Common denial reasons (and how to address each)

"Not medically necessary." This is the most common denial and the most commonly overturned. Ask your insurer for their exact medical necessity criteria in writing, then have your provider document specifically against each criterion: BMI history from multiple visits, weight-related comorbidities with lab evidence (A1C, lipid panels, blood pressure readings, sleep study results), and previous treatment attempts with dates.

"Step therapy required." Many plans require you to try cheaper medications first (like phentermine or metformin off-label). If you've already tried these, document each attempt with start dates, duration, results, and reason for discontinuation. If you haven't tried them, discuss with your provider whether a brief trial could satisfy the requirement.

"Formulary exclusion." Some plans explicitly exclude anti-obesity medications. This is harder to overturn but still worth attempting, especially if you have cardiovascular disease. The SELECT trial demonstrated that Wegovy reduces cardiovascular events by 20% in adults with obesity and heart disease, providing an alternative coverage basis under a cardiovascular indication.

Practical appeal tips

Request the plan's specific denial criteria before writing your appeal. The denial letter should include a reference code or medical policy number. Address the exact stated reason, with documentation that directly contradicts the denial basis. Include peer-reviewed citations supporting the medical necessity of GLP-1 therapy for your specific conditions.

Submit through the insurer's secure portal or fax (never email, as it may not be HIPAA-compliant). Keep copies of everything and note submission dates. Most plans must respond within 30 days for prior authorization appeals and 60 days for claims appeals.

Direct-to-Consumer Platforms

Eli Lilly launched LillyDirect, a direct-to-consumer platform that offers Zepbound at reduced self-pay prices without requiring insurance:

• 2.5 mg (starting dose): $299 per month
• 5 mg: $399 per month
• 7.5 mg to 15 mg: $449 per month

These prices represent 59% to 72% savings compared to retail pharmacy prices. The medication comes in single-dose vials (not the pre-filled pens used through traditional pharmacies) with free home delivery or Walmart pharmacy pickup.

Important detail: For doses 7.5 mg and above, the $449 price requires refilling within 45 days of the previous delivery. Missing that window resets the price to $599 to $1,049 depending on dose.

Novo Nordisk offers NovoCare self-pay pricing for Wegovy at $349 per month for all doses, with an introductory rate of $199 per month for the first two fills (through March 2026).

These prices remain substantial, but they're roughly a third of the retail cost, and they don't require insurance approval, prior authorization, or appeal processes.

Clinical Trials

Clinical trials offer a pathway to free access to GLP-1 medications (including next-generation drugs not yet on the market) while contributing to research that helps others.

As of 2026, active trials are recruiting for:

• Orforglipron (Eli Lilly): an oral GLP-1 (a pill, taken daily, rather than a weekly injection) in Phase 3 trials with 600+ participants across 105 locations. Early results show up to 12.4% body weight reduction over 72 weeks.
• Tirzepatide trials at multiple academic medical centers, including long-term studies examining body composition and bone health effects.
• Combination trials comparing semaglutide and tirzepatide head-to-head at institutions like the Mayo Clinic.

How to find trials: Search ClinicalTrials.gov for "obesity" or "weight loss" and filter by your location and recruiting status. Platforms like WithPower.com and ResearchMatch.org make the search process more accessible.

What to know: Trials typically provide the medication and medical monitoring at no cost. Some offer compensation for time and travel. You may be assigned to a placebo group (though many trials use active comparators rather than placebo). Eligibility criteria vary: most require a BMI of 30 or above (or 25+ with weight-related conditions) and exclude people already on weight loss medications.

State Medicaid Coverage

If you're on Medicaid, coverage depends entirely on your state. As of 2026, only 13 states cover GLP-1 medications for obesity through Medicaid fee-for-service: California, Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, New Hampshire, North Carolina, Pennsylvania, Rhode Island, Virginia, and Wisconsin.

The landscape is shifting: some states have recently added coverage (Missouri, Tennessee, Utah) while others have eliminated or narrowed it. Even in states that cover GLP-1s for obesity, strict prior authorization requirements and BMI thresholds apply.

If your state doesn't cover weight loss medications through Medicaid, this is a systemic gap, and advocacy organizations like the Obesity Action Coalition are working to expand coverage state by state.

What If None of These Work?

Here's the reality that needs saying: even with all these pathways, millions of people still cannot access GLP-1 medications. The Patient Assistance Programs exclude weight loss indications. Savings cards exclude the uninsured, Medicare, and Medicaid populations. Insurance denials, while often overturnable, still block many patients. Direct-to-consumer pricing, while improved, is still $300+ per month, indefinitely. Clinical trial spots are limited and location-dependent.

This is a systemic problem. The pharmaceutical pricing structure, the insurance coverage gaps, and the policy landscape all contribute to a situation where effective medications exist but remain out of reach for the people who need them.

If you've exhausted every pathway and still can't access GLP-1 therapy, the question becomes: what else targets the same mechanisms?

GLP-1 drugs work primarily by reducing food noise, the persistent mental chatter about food that drives overeating. They dampen cravings, reduce the reward response to highly palatable foods, and create a quieter relationship with eating. These are real neurological effects, and they're the primary reason the drugs produce sustained weight loss.

The cheaper alternatives to Ozempic span a wide range, from OTC supplements with modest effects to behavioral approaches that target the same neural pathways through different mechanisms. Among the behavioral approaches, self-hypnosis works with the subconscious patterns that drive food-seeking behavior, addressing the cravings, emotional eating responses, and automatic food habits that food noise amplifies. The cost structure is fundamentally different: a finite investment in changing patterns, rather than an ongoing pharmaceutical expense.

These aren't equivalent to GLP-1 drugs in speed or magnitude of effect. Honesty about that matters. What they offer is accessibility. They're available to anyone, regardless of insurance status, income, or location. And for many people, addressing the behavioral and subconscious roots of overeating produces meaningful, lasting change.

The Bottom Line

Work through the pathways in this order:

1. Check your insurance. Even if you've been denied, appeal. The success rates justify the effort.
2. Apply for manufacturer programs. If you have type 2 diabetes and meet income criteria, PAPs provide free medication.
3. Use savings cards. If you have commercial insurance, these can reduce costs to $25 per month.
4. Explore direct-to-consumer options. LillyDirect and NovoCare self-pay pricing are the most accessible non-insurance pathways.
5. Search for clinical trials. Free access plus contribution to medical research.
6. Check Medicaid coverage. If applicable, verify your state's current policy.

If none of these work, explore the natural alternatives that address the same underlying drivers. The goal is the same: a quieter mind around food, reduced cravings, and a sustainable relationship with eating. The pathway there has more than one route.

This article is for educational purposes and does not constitute medical or financial advice. Eligibility requirements, program details, and pricing change frequently. Verify current information directly with manufacturers, insurers, and program administrators. Never start or modify prescription medication without consulting a healthcare provider.

Ready to stop fighting your cravings and start reprogramming your mind for lasting success? The Hypna AI 21-day self-hypnosis program is designed to help you rewire subconscious patterns and build a healthier relationship with food from the inside out.